Overview

As a spin-off from Prof. Alfred Maelicke's Laboratory of Molecular Neurobiology at the Institute of Physiological Chemistry and Pathobiochemistry, University of Mainz Medical School, Germany, Galantos Pharma GmbH capitalizes on a technology platform centered around nicotinic acetylcholine receptors (nAChRs), which it fully owns.

These receptors are involved in learning and attention - and loss of nicotinic receptors is a common feature in Alzheimer‘s Disease (AD). On a molecular basis, these receptors are crucial not only for the communication of nerve cells, but also for neuronal survival and apoptosis.

Galantos Pharma´s technology platform allows for the study and elucidation of the mechanism of action of anti-dementive and neuroprotective drugs, in particular in respect to effects on nicotinic acetylcholine receptors and the development of novel lead structures and drug targets for the treatment of AD.